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ABSTRACT
Introduction: BRAF mutant colorectal cancer carries a poor prognosis which is 
thought to be related to poor response to conventional chemotherapy. BRAF mutation 
is associated with the serrated tumour phenotype. We hypothesised that one of the 
mechanisms by which BRAF mutant colorectal cancer demonstrate poor outcomes 
with chemotherapy is abnormal gene methylation
Methods: The Cancer Genome Atlas (TCGA) methylation data was analysed using 
a linear regression model with BRAF mutation as an independent variable. Expression 
datasets were also obtained to correlate functional changes. Top differentially 
methylated probes were taken forward for validation by methylation pyrosequencing. 
These probes were analysed on a cohort of patients enriched for BRAF mutations 
taken from the VICTOR and QUASAR2 studies. 
Results: In an analysis of 91 tumours (9 BRAF mutant, 82 wild type), the Illumina 
probe cg11835197 was the probe identified as top differentially methylated (p = 
2.56x10-7, Bayes Factor (BF) =6.54). This probe covered a region -413bp from the 
promoter region of TFAP2E. We found a complex pattern of CpG specific methylation 
of this region which was associated with both overall (p=0.044) and disease free 
(p=0.046) survival. 
Discussion: BRAF mutant tumours may attain part of their chemoresistance from 
abnormal TFAP2E methylation, which has not previously been described. 
INTRODUCTION
Previous studies have clearly shown that patients 
with BRAF mutant colorectal cancer (CRC) receiving 
adjuvant chemotherapy following resection have a worse 
outcome compared to their BRAF wild type counterparts 
[1, 2]. This inferior outcome appears to specifically relate 
to patients receiving adjuvant 5-fluorouracil/leucovorin 
(FU/LV) alone. In the CALGB 89803 study BRAF 
mutant stage III patients treated on the control arm of FU/
LV alone had a significantly reduced disease free survival 
(DFS) (HR = 1.83) and overall survival (OS) (HR = 2.43) 
compared with BRAF wild type patients treated with the 
same regimen [1]. This inferior outcome was not seen in 
BRAF mutant patients treated with IFL and indeed there 
was a trend towards improved outcome for the addition of 
Irinotecan in BRAF mutant patients, a trend that was not 
seen in BRAF wild type patients. In a combined analysis 
of the National Surgical Adjuvant Breast and Bowel 
Project C-07 and C-08 trials of adjuvant therapy OS 
was again inferior in BRAF mutant microsatellite stable 
(MSS) patients: BRAF mutant patients with deficient 
mismatch repair (MSI) had outcomes similar to BRAF wt 
MSS patients [2]. In the C-07 study which demonstrated 
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a benefit for the addition of oxaliplatin to adjuvant FU/
LV, there was no significant interaction between BRAF 
mutation status and the beneficial effect of oxaliplatin.
The molecular basis of this inferior outcome of 
BRAF mutant patients receiving adjuvant FU/LV is 
unknown. A recent study has demonstrated an important 
link between hypermethylation and chemo-resistance in 
CRC [3]. Fifty-one percent of CRC patient samples were 
found to have hypermethylation of TFAP2E. TFAP2E is 
a member of the AP2 family of transcription factors 6 
and has a putative link as a tumour suppressor. The AP2 
transcription factor family consist of five subtypes, AP2-
α,β,χ,δ and AP2-ε, and are located predominantly in the 
nucleus where they regulate transcription and interact 
with other signal transduction pathways., AP2-a has been 
shown to modulate the Wnt signalling pathway 7 by 
interacting with the Adenomatous Polyposis Coli (APC) 
protein, the key protein in colorectal cancer development. 
It was shown that TFAP2E negatively regulated DKK4 
and expression of DKK4 mediated chemoresistance 
to fluorouracil but not to irinotecan or oxaliplatin. In a 
cohort of patients treated with fluorouracil/oxaliplatin 
TFAP2E methylation was significantly associated with 
lack of response to therapy. The authors hypothesised that 
TFAP2E hypermethylation mediated clinical resistance 
to fluoropyrimidine based doublet therapy via DKK4-
mediated fluorouracil resistance.
Zhang et al [4] used high resolution melt analysis 
of TFAP2E methylation in 311 colorectal cancer patients. 
They found that hypermethylation conferred a survival 
advantage in these patients, and that patients with 
hypermethylation in TFAP2E presented with earlier stage 
tumours, had less invasion, fewer positive lymph nodes 
and had better tumour differentiation. 
A specific association with TFAP2E 
hypermethylation and BRAF mutation which in all 
stages is associated with the hypermethylator phenotype 
was not made in either of these studies. It has recently 
been described [5] that transcriptional control of 
gene expression via promoter methylation is a more 
complex process that previously understood. In fact, 
hypomethylation within CpG shore regions as well as 
hypermethylation, can cause decreased expression of 
a gene. Vanderkraats et al [5] demonstrated patterns of 
adjacent short stretches of hypermethylation followed by 
hypomethylation downstream of the transcription start site 
of a gene were the most strongly linked correlates with 
reduction of expression of genes.
Given the well documented association between 
BRAF mutant CRC and the CpG island methylator 
phenotype (CIMP) [6, 7], we examined the colorectal 
cancer TCGA to identify genes that were highly 
differentially methylated between BRAF mutant and 
wild type cases to identify candidates worthy of further 
analysis to unravel the clinical finding of poor outcomes 
after adjuvant FU/LV . We found that the most significant 
hit was a probe associated with the TFAP2E gene. This 
was intriguing given the data of Ebert and colleagues 
who had shown that hypermethylation of TFAP2E was 
a marker of FU resistance (not irinotecan or oxaliplatin 
resistance) in colorectal cancer. However, in that study 
there was no reported differential methylation in TFAP2E 
between BRAF mutant and wild type CRC. This prompted 
us to undertake a precise evaluation of methylation across 
TFAP2E in BRAF mutant CRC in order to understand its 
full complexity
RESULTS
Initial discovery phase
For the TCGA methylation dataset, 92 level 1 
methylation dataset files (as at the time of the study, 
these were the only ones available for level 1 download 
along with mutation data) were retrieved for tumour 
samples, of which 9 possessed BRAF V600E mutations, 
and 83 were wild type for BRAF mutations. Analysis 
was successful and the top hit was Illumina probe 
cg11835197 (Chr1:36038515-36038515) with a log 
fold change of 1.73, p = 2.56x10-7, Bayes Factor (BF) 
=6.54. This was just upstream of the 1st CpG island of 
TFAP2E (Figure 1, Probe A), the probe being -413bp 
of the island start site. TFAP2E is a gene involved as a 
upstream regulator of DKK4, a Wnt signalling pathway 
associated gene, previously described as being implicated 
in chemoresistance to 5-FU chemotherapy by Ebert 
et al[3]. The remaining 6 probes, all with BF > 5 are 
shown in Table 1. The genes identified in this set include 
GDPD2 (which hydrolyses glycerophosphoinositol to 
produce inositol 1-phosphate and glycerol), SETX (a 
RNA helicase), ACSL5 (a bHLH transcription factor), 
EPOR (the erythropoietin receptor), PEG10 (paternally 
expressed 10, a gene of unknown function), and a CpG 
island adjacent to ZC3H3 and RHPN1. 
On further study of the Ebert et al paper, it was noted 
that TFAP2E possesses two associated CpG islands, one 
within exon 1 (CpG Island I) of TFAP2E and other within 
intron 3 (CpG Island II, Figure 1). In the Ebert paper, the 
island (CpG Island II) within intron 3 was noted to be 
differentially hypermethylated in chemoresistant tumours; 
however they found that that the island within exon 1 was 
universally hypermethylated by bisulphite sequencing. 
Probe A identified by our study lies at 413bp from the 
start of CpG island 1, within the shore of the promoter 
associated CpG island of TFAP2E. This region had not 
specifically been studied in detail by Ebert et al as it was 
thought to be uniformly hypermethylated. Correlation 
of TFAP2E methylation at cg11835197 with expression 
was obtained using the TCGA dataset, and demonstrated 
that there was a weak but significant negative correlation 
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Table 1: Table of top ranked probe identifiers ranked by Bayes factor (largest first) comparing BRAF mutant 
vs. BRAF wild type tumours in TCGA methylation dataset.
Rank Illumina probe ID
Log [Fold 
change] t P Value
Adjusted p 
value
Bayes fac-
tor Gene
1 cg11835197 1.73 5.55 2.56E-07 0.003 6.54 TFAP2E
2 cg25685838 2.17 5.41 4.77E-07 0.003 5.97 GDPD2
3 cg06353948 3.19 5.37 5.61E-07 0.003 5.83 SETX
4 cg13849691 3.35 5.37 5.66E-07 0.003 5.82 ACSL5
5 cg24477567 1.99 5.20 1.15E-06 0.003 5.18 EPOR
6 cg06695761 1.63 5.18 1.23E-06 0.003 5.13 PEG10
7 cg03870862 2.20 5.18 1.25E-06 0.003 5.11 ZC3H3
Table 2: Adjusted logistic regression model of BRAF mutation status vs. methylation at region surrounding 
Illumina probe ID cg11835197 consisting of 2 CpG’s.
Variable Coefficient 95% CI p-value
CpG 1 0.260 0.038-0.482 0.022
CpG 2 -0.258 -0.448--0.068 0.008
Chromosomally unstable tumour
(1=CIN) -1.266 -2.905-0.373 0.13
Gender (1=male) -1.535 -3.149-0.078 0.062
MSI tumour
(1= MSI) 0.486 -1.379-2.352 0.609
Age 0.056 -0.032-0.145 0.214
Figure 1: Diagrammatic representation of TFAP2E CpG islands and their relationship to the TFAP2E gene (Adapted 
from Ebert et al). 
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between TFAP2E methylation and expression at our 
identified region (Spearman p=0.044, rho = -0.13), 
i.e. as methylation of TFAP2E in this region increased, 
expression of TFAP2E decreased. We checked methylation 
in the Ebert region against TFAP2E gene expression, and 
also found significant correlations (Spearman p=0.04).
Because of our findings and because differential 
methylation observed within the shores of CpG islands are 
the most transcriptionally relevant[5], we decided to study 
this region, and the original region described by Ebert et 
al in more detail on an enriched BRAF mutant study set.
Validation
We successfully carried out bisulphite 
pyrosequencing on all supplied samples from the VICTOR 
and QUASAR2 studies. Of the 96 supplied tumour 
samples, 83 were BRAF mutant (all V600E) as previously 
determined by Sanger sequencing. A simple analysis, 
comparing BRAF mutation status vs. methylation was 
carried out. At the area downstream of CpG island 1 (probe 
cg11835197), which contained 2 CpG’s, the first CpG, 
corresponding to Illumina probe ID cg11835197 seen in 
Table 3: Table of percentage methylation across differentially methylated region identified by Ebert et al 
within intronic region of TFAP2E.
Average methylation
CpG BRAF Wild type BRAF mutant p-value (Wilcoxon)
1 38.7% 45.5% 0.18
2 40.5% 47.0% 0.21
3 36.8% 44.5% 0.14
4 34.5% 41.2% 0.12
5 34.3% 41.5% 0.15
6 36.2% 42.0% 0.27
7 40.1% 48.5% 0.12
8 45.6% 55.6% 0.11
9 36.7% 43.7% 0.17
10 33.3% 40.7% 0.12
11 27.7% 34.8% 0.14
Figure 2: Scatter plot of TFAP2E expression vs. methylation showing correlation between methylation of TFAP2E expression and 
methylation at probe cg11835197.
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the array experiment was not significantly differentially 
hypermethylated (p=0.15, Wilcoxon). As a consequence 
of the pyrosequencing assay design, the assay covered 
a second CpG +6bp upstream of cg11835197, which 
on analysis was found to be significantly differentially 
hypomethylated (p=0.0032, Wilcoxon), with BRAF 
mutant tumours having a median of 18.5% for mutated 
tumours and 26.0% for wild type tumours. 
Methylation of DNA is a complex phenomenon 
and may be affected the factors such as age (which 
increases methylation linearly), gender (bias towards 
females have hypermethylated tumours) and co-incident 
methylation of adjacent CpG’s. Because of the potential 
for bias by these factors, we constructed a multivariate 
logistic regression model to correct for the effects of these 
potential confounders. We used BRAF mutation status 
as the dependent variable and percentage methylation 
in our identified region at CpG1 and CpG2, MSI status, 
age, gender, and CIN status. Variables were removed 
sequentially from the model at a threshold of p<0.05, 
using reverse stepwise methodology. In this model (table 
2), the methylation of TFAP2E was shown to increase 
Table 4: Table of cox regression model of TFAP2E methylation in overall and disease free survival. 
Variable
Overall survival Disease free survival
HR 95% CI P HR 95% CI P
TFAP2E CpG1 Above threshold 
Below threshold (baseline)
1.08
-
0.43-2.83
-
0.844
-
0.90
-
0.37-2.17
-
0.818
-
TFAP2E CpG2 Above threshold 
Below threshold (baseline)
0.34
-
0.12-0.97
-
0.044
-
0.40
-
0.16-0.98
-
0.046
-
MSI status Microsatellite unstable
Microsatellite stable (baseline)
0.45
-
0.172-1.18
-
0.104
-
0.34
-
0.14-0.84
-
0.019
-
Gender Male
Female (baseline)
1.26
-
0.55-2.93
-
0.581
-
1.45
-
0.69-3.08
-
0.330
-
Age 
(years) 1.04 0.98-1.09 0.151 1.03 0.98-1.08 0.200
Chemotherapy
Chemotherapy given
Chemotherapy not given (base-
line)
2.45
-
0.52-11.46
-
0.255
-
2.57
-
0.66-10.1
-
0.175
-
Location Left colon
Right colon (baseline)
1.13
-
0.42-3.06
-
0.811
-
1.14
-
0.47-2.74
-
0.769
-
KRAS mutation Mutation
No mutation (baseline)
9.61
-
0.79-116.6
-
0.076
-
9.27
-
1.42
-
60.7
-
Stage T4
< T4 (baseline)
0.62
-
0.26-1.47
-
0.278
-
0.73
-
0.33-1.61
-
0.435
-
Lymph node status
(1=LN positive)
Positive lymph nodes
Negative lymph nodes (baseline)
1.73
-
0.62-4.87
-
0.298
-
2.57
-
0.65-10.08
-
0.175
-
Figure 3: Kaplan-Meier plot of overall survival vs. 
TFAP2E methylation showing decreased overall survival in 
hypomethylated tumours.
Figure 4: Kaplan-Meier plot of disease free survival vs. 
TFAP2E methylation showing decreased disease free survival in 
hypomethylated tumours
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significantly in CpG1 (coef = 0.260, z=2.16, p=0.022), 
and significantly decrease in CpG2 (coef =-0.258, z=-2.55, 
p=0.008) in BRAF mutated tumours. 
We also carried out “safety checks” on this model 
to ensure bias was not being introduced inadvertently. 
BRAF mutation is known to be associated with tumours 
occurring in females and we found that in this cohort was 
shown to be negatively correlated with male gender (coef 
= -1.54, z=-2.16, p=0.062). Chromosomal instability and 
BRAF mutation are also almost always mutually exclusive 
and in this cohort BRAF mutation and chromosomal 
instability tended towards being mutually exclusive 
(coef = -1.27, z=-2.23, p=0.13). A Hoesmer-Lemeshow 
goodness of fit test demonstrated a good model fit for the 
dataset (p=0.36). 
We then decided to compare our results 
to the previously observed region of differential 
hypermethylation in CpG Island II from Ebert et al. 
In CpG island II, which contained 11 CpG’s, when 
added to our logistic regression model, none attained 
significance associated with BRAF mutation (Table 3), 
setting the threshold at p<0.05. We observed uniform 
hypermethylation across the Ebert region, with no 
differential methylation seen between BRAF mutant and 
BRAF wild type tumours.
Effect on survival in the VICTOR & QUASAR2 
cohorts
In order to model the effect on survival on the 
VICTOR & QUASAR2 cohort for whom methylation data 
and survival data was available (n=96), we constructed 
a multivariate Cox regression model comparing overall 
survival (OS) and disease free survival with available 
clinicopathological variables. These variables were age, 
gender (male = 1, female = 0), use of chemotherapy, 
chromosomal instability, microsatellite instability status, 
KRAS mutation status and BRAF mutation status (in 
order to correct for the confounder of poorer survival in 
BRAF mutant patient). In order to more easily model the 
effect of changes in methylation at the 1st and 2nd CpG‘s 
at Probe A in TFAP2E, we thresholded the variable such 
that a cut-off of 20% was chosen to differentiate between 
the “hypermethylated” and “hypomethylated” groups, 
based on a non-parametric receiver-operator curve 
analysis demonstrating that this percentage methylation 
differentiated maximally between the two groups of 
methylation. 
Using this cut-off, the relationship between TFAP2E 
hypermethylation at CpG1 and both overall (p=0.844) and 
disease free survival (p=0.818) did not reach significance. 
For hypomethylation at CpG2, there were significant 
associations between both overall (p=0.044) and disease-
free (p=0.046) survival (Figure 2 & Figure 3). We did not 
find any significant association between BRAF mutation 
and either overall or disease free survival when corrected 
for overall TFAP2E methylation. 
On examination of CpG island II in the intronic 
region, because of the uniformity of methylation observed, 
we took the average methylation across all 11 CpG’s and 
used it in a Cox regression model, correcting for age, 
gender, chemotherapy status, MSI status, CIN status and 
BRAF/KRAS mutation status. There was no association 
between methylation across CpG island II and overall 
(HR 1.38, 95% CI 0.16-12.1, p=0.771) or disease free (HR 
1.76, 95% CI 0.21-14.75, p=0.602) survival.
CONCLUSIONS
In our study we have used the TCGA dataset to 
identify the changes that are seen in methylation in BRAF 
mutant tumours. We found, using an unbiased hypothesis 
free approach that these tumours are associated with 
changes in methylation across the TFAP2E promoter 
region, specifically locus specific hypomethylation of 
a CpG within the shore of the CpG island of TFAP2E 
associated promoter region. Ebert et al [3] examined the 
rates of BRAF mutation in association with promoter 
hypermethylation in their study group, however they found 
that there was no association with BRAF mutation. This 
is because the region of the CpG island they studied was 
not the one that was transcriptionally relevant to TFAP2E 
expression, and the use of Methylight missed subtle 
single CpG changes that are important in the regulation 
of transcription. We believe this as their observed 
region had little variation in methylation observed 
using pyrosequencing; thus the differences observed in 
expression could not be related to methylation change at 
this region, despite the fact we have also demonstrated an 
association between methylation and expression here. The 
observed phenomenon whereby BRAF mutated tumours 
demonstrate resistance to 5-FU-based chemotherapy may 
be associated with the phenomenon of differential changes 
in TFAP2E promoter methylation. 
We found similar outcomes to Zhang et al [4], in 
that hypomethylation in TFAP2E was associated with 
poorer survival. However, the location of hypomethylation 
was different in our study, with hypomethylation in the 
CpG shore downstream of the promoter region being 
significantly associated with prognosis. In the Zhang 
paper, they found hypomethylation within the region 
described by Ebert et al [3] within an intronic region of 
TFAP2E. They used a high resolution methylation melt 
analysis which covered 11 CpG’s. This has the weakness 
in that all CpG’s are treated as a single unit [8], rather than 
in pyrosequencing which was utilised in our study which 
can detect subtle single CpG changes in methylation. 
We agree that TFAP2E expression is linked to 
chemoresistance, however we believe the mechanism 
of this resistance via promoter methylation is more 
complex. Our study has demonstrated that there is a 
significant association on multivariate analysis towards 
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hypermethylation in the 1st CpG and hypomethylation in 
the 2nd CpG of our identified region, and this is linked to 
both BRAF mutation status and lower overall and disease 
free survival. This would fit with the fine control of 
gene expression seen by Vanderkraats et al [5], whereby 
regions of hypermethylation followed by hypomethylation 
is seen, and transcriptional control to the single CpG 
level has been demonstrated in multiple studies [9, 10]. 
Using the TCGA dataset, we have also demonstrated that 
methylation change in this region is linked to TFAP2E 
expression. 
It was found by Ebert et al [3] that cell 
lines transfected with a TFAP2E clone (leading to 
overexpression) had poorer survival, i.e. they were 
chemosensitive, however they did not find a conclusive 
link between methylation in their CpG island and 
TFAP2E expression. Ebert et al [3] used 5-azacytidine 
to demonstrate changes in TFAP2E expression in cell 
lines, however they did not find conclusive changes in 
all cell lines studied, with only 2 cell lines demonstrating 
a change in TFAP2E expression with 5-azacytidine 
exposure. The use of 5-azacytidine, which causes global 
hypomethylation across the genome is the only tool 
currently available to study methylation changes in cells 
and because of its genome wide effects may lead to the 
loss of subtle mechanistic changes. 
We have not replicated the finding by Ebert et al 
[3] that hypermethylation in their identified region is 
associated with poorer outcome on adjuvant FU/LV. We 
have found, that hypomethylation within a specific CpG 
identified in our study is related to both overall and disease 
free survival following adjuvant FU/LV based therapy; 
however this may be a phenomenon related to the fact 
that these tumours are BRAF mutated and thus will have 
a poorer survival, however we took account of this in our 
regression model and TFAP2E methylation change still 
remained significant. We agree that TFAP2E/DKK4 plays 
a role in chemoresistance, and we further propose that this 
is also linked with BRAF mutation and is potentially also 
responsible for their chemoresistance via dysregulation of 
the MAPK pathway. Further study is needed in a larger 
cohort to identify the potential of these identified changes, 
and also to fully understand the mechanisms that lead to 
BRAF tumours becoming chemoresistant and having a 
poorer prognosis, as this is unlikely to be due to a single 
pathway phenomenon. 
MATERIALS AND METHODS
Discovery phase using TCGA dataset
In order to carry out an initial analysis of differences 
in hypermethylation between BRAF mutant and BRAF 
wild type tumours, Level 1 Illumina Human Methylation 
450 data from the COAD colon cancer dataset from the 
NIH Cancer Genome Atlas (TCGA) was downloaded 
from the data repository in August 2013 (https://tcga-data.
nci.nih.gov/tcga/). This data was correlated by BRAF 
mutation status by downloading mutation data from 
sequencing datasets from the same repository. Sample IDs 
were correlated using the TCGA sample ID.
Level 1 methylation data was imported in R v 
2.6.1, filtered according to the methodology of Triche et 
al [11], SWAN normalised [12] and an linear fit model 
with empirical shrinkage of T-statistics fitted, using BRAF 
mutation status as a dependent variable, correcting for age 
and gender. Multiple testing correction was performed 
using the Benjamini-Hochberg (BH) adjustment. Top 
probes were sorted by Bayes factor (with significant BF 
> 5) and exported to Microsoft Excel for correlation 
with Illumina probe identifiers as well as chromosomal 
coordinates.
Assay design & validation on colorectal tumour 
set
In order to study a population enriched for BRAF 
mutation, 96 tumour DNA samples from the VICTOR 
and QUASAR2 trials were used. The VICTOR study 
[13] was a randomised controlled trial of rofecoxib, a 
COX2 inhibitor against placebo in 908 patients in the 
post-adjuvant prevention of recurrence of colorectal 
cancer. The QUASAR2 study [14] was a randomised 
controlled trial comparing capecitabine vs. capecitabine 
+ bevacizumab as adjuvant therapy for CRC. The 
VICTOR study received ethical approval from West 
Midlands Multicentre Research Ethics Committee and 
the QUASAR2 study from the Metropolitan Multi-centre 
Research Ethics Committee (ref: 04/MRE11/18). DNA 
extracted from the VICTOR and QUASAR2 samples 
was enriched for tumour material by macrodissection 
from slides. Samples were also previously genotyped for 
KRAS, NRAS, PIK3CA, TP53 and CDC4 mutations by 
Sanger sequencing, chromosomal instability status using 
image cytometry ploidy [15] and microsatellite instability 
status by genotyping of the BAT25, BAT26 and D2S123 
polymorphic loci. 
Top hits from the methylation association study 
were validated by means of bisulphite pyrosequencing. 
Assay design was carried out using Qiagen Pyromark 2.0 
software. The region of interest was chosen flanking the 
Illumina probe sequencing +/-200bp, with the sequence 
being exported from the UCSC Genome Browser 
(Genome v37 release). Standard assay design conditions 
were utilised, with the target CpG from the probe 
highlighted as the region of interest. 
Two sets of probes designed for study of 
TFAP2E methylation. For study of the differentially 
hypermethylated site observed in the TCGA dataset 
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(TFAP2E-Probeset-1), primers designed were Fwd- 
AGTAGATAGGTTGGAGTTTTTAGTTTATA; Rev 
– [Btn] CCTTACCTTTAAACAAAACACTATTCT; 
Seq – GGTTGGAGTTTTTAGTTTATAA. The 
designed amplicon encompassed two CpG’s – 
firstly the CpG covered by the Illumina probe and 
the second +6bp upstream of the first probe. For 
study of the original TFAP2E hypermethylation site 
seen by Ebert et al, primers designed were Fwd – 
TTGGTGAGAAAGGGAGGTAGTT; Rev - [Btn]
ACCCTACCAACTCCAAATACCTCTAC and Seq - 
TGTAGTTTTAGTTTTATTTTAGAAG and covered 
eleven CpG’s within this region. 
Primers were utilised in standard (20uM) 
concentrations in a PCR reaction using the Pyromark 
PCR kit. For each PCR reaction, 1uL of bisulphite 
converted DNA was made up in a reaction with 12.5uL 
of Pyromark PCR master mix, 0.3uL of forward primer, 
0.3uL of reverse biotinylated primer, 3uL of Q solution, 
5uL of Coral Load concentrate, 1.5uL of 20mM MgCl2 
made up to a total of 25uL reaction volume with ddH2O. 
PCR conditions were according to Qiagen specifications 
with an annealing temperature of 56C (experimentally 
determined by gradient PCR). After PCR, 5uL of product 
was run on a 1.5% agarose gel to ascertain success of 
the reaction and successful reactions were taken forward 
to pyrosequencing. Pyrosequencing was performed 
according to manufacturer’s specifications using a Qiagen 
PyroMark 96 ID instrument, diluting 20uM sequencing 
primer to 1:50 for use in sequencing. Pyrosequencing 
runs were subjected to quality control using Qiagen Pyro 
Q-CPG software and only reactions passing QC measures 
were used. A random selection of 10% of runs was 
duplicated to ensure consistency. 
Expression/methylation correlation
In order to validate the correlation between 
expression and methylation in TFAP2E, Level 3 data for 
gene expression determined via RNA-seq and methylation 
data via the Illumina HumanMethylation450 BeadChip 
was downloaded from the TCGA data portal in November 
2013 (https://tcga-data.nci.nih.gov/tcga/). Expression data 
was log-normalised and correlated with methylation via 
Spearman’s’ Rho using Stata 12.1 (StataCORP, TX)
Outcomes for TFAP2E on VICTOR/QUASAR2
Survival data was available for both the VICTOR 
study and QUASAR2 studies, in this a multivariate Cox 
regression model was set up using overall and disease free 
survival as separate dependent variables with mutational 
status, microsatellite instability status, age, T stage, N 
stage, chemotherapy status and location (right colon vs. 
left colon). All statistical analysis was performed in Stata 
12.1 (StataCORP, TX).
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